Entresto, a medication commonly used for people with heart failure, may interfere with blood tests for Alzheimer’s disease. This has been shown by a study published in the journal. JAMA Neurology.
Alzheimer’s disease is associated with the accumulation of beta-amyloid protein aggregates in the brain. Recently, drugs have been approved to reduce this process. Beta-amyloid accumulation in the brain needs to be confirmed by methods such as cerebrospinal fluid testing or a PET scan of the brain. However, these procedures are invasive, laborious and expensive. Therefore, less invasive and more accessible tests have been proposed.
A test for Alzheimer’s disease is based on measuring the ratio of two different forms of amyloid beta in blood plasma. 92 patients with heart failure participated in the new study. They took the drug Entresto, which contains the ingredients sacubitril and valsartan or just valsartan. They were followed for almost a year and had two tests for Alzheimer’s disease. Taking Entresto led to false positive test results.
About 40% of people with heart failure also have memory and thinking problems. The new study suggests that the Alzheimer’s disease test being studied may not be suitable for many of these patients.
Previous scientists to create A factor that can increase the risk of severe atherosclerosis by 1.8 times.